burnchat
20 Apr 2018
Re: Strange nobody ... added comment Jumping ship before TO iMHO
burnchat
19 Apr 2018
Re: Strange nobody ... added comment Trading action today would seem to be consistent with a RNS tomorrow...
dave297
18 Apr 2018
Likely bidders I appreciate that there are many reasons why certain large Pharmas would not be interested in acquiring us , due to our various partnerships/agreements with competing pharmas.Fortunately there are many reasons why several of them may well be tempted to bid for & let us hope that the upturn in the fortunes of Pacira is a sign that ,after firing blanks since the ill fated merger with SKP (my introduction here was via SKP) that we are now in a period during which positive news will prevail & our SP will improve ahead of expected improvements in our prospects , before the "inevitable" bid by one, or more, of the various interested parties.I doubt whether our CEO or FD are happy treading water & an acceptable exit would be a great outcome for them & hopefully us too.
Ambiorix1
18 Apr 2018
Re: Strange nobody ... added comment There is a critical need in the postsurgical setting for non-opioid options that turn off pain at the surgical site and reduce the need for opioids,” said Jeffrey Gadsden, MD, Chief of Orthopaedics, Plastics, and Regional Anesthesiology and Associate Professor of Anesthesiology at Duke University School of Medicine. “The ability to provide effective regional analgesia with a single dose of EXPAREL is a tremendous victory for patients and advances the imperative need for low- or no-opioid pain management strategies.”
Ambiorix1
18 Apr 2018
Strange nobody noticed this one recently... Shares of Pacira Pharmaceuticals moved up more than 13% on Friday (week ago) after the company announced that the FDA has approved the label expansion of its flagship product, Exparel.The FDA approved Pacira’s supplemental new drug application seeking expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia. However, the FDA’s approval came as a surprise after an FDA Committee voted six to four against approval of the expanded indication in February.With this approval, Exparel is the first long-acting, single-dose nerve block available for patients undergoing upper extremity surgeries, such as total shoulder arthroplasty or rotator cuff repair.Exparel is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce post-surgical analgesia.The approval will allow clinicians to potentially do away with the need for cumbersome catheters and pumps that are used to extend the duration of regional analgesia.This definitely means more royalties to come for Vectura (increased % of sales and probably new milestones).Ambiorix.
Andy Reilly
17 Apr 2018
Re: Increase in price VEC was pretty overbught on the chart so to expect more (just a hope in my case) was a bit much, BUT lets hope the SP is on the road to recovery (assuming markets can hang on and there isNT another bout of hig anxiety!!!! ATB to you and other holders - ARWELL... the 200 day EMA offers support for now! So not all bad!
Chicken Lips
17 Apr 2018
Re: Increase in price Andy I agree. The only news yesterday seemed to be Shire and the sale of the Oncology division possible scuppering the Takeda deal. Must be this but seems a bit of a stretch.
Andy Reilly
17 Apr 2018
Re: Increase in price CL - it is strange, and that was my thought too - I think brokers repoerts are treated pretty skeptically generally! Who knows! Markets are a constant source of amazement... Lets just hope IF it is a TO that the price isnt too bad! ATB to all holders, and lets hope for better today!
Chicken Lips
16 Apr 2018
Re: Increase in price Seems to big to be simply a broker upgrade both in volume and rise or a rerating. No new news either. This has a takeover written all over it but no takeover...how strange.
raptor66
16 Apr 2018
Re: Increase in price From Evening Standard:Vectura (ticker: VEC), the pharmaceuticals player, had a good day after rumours of a broker upgrade. Up 4% at 98p, it’s having something of a rally lately after bottoming at 68p last month. Could be time for a re-rating of the inhaled medicines expert, say brokers. Again, bid stories might be helping it up after pharmaceuticals giant Shire sold its oncology business for a bumper sum. Volumes are big today, too. An insider at the firm tries to spin it that investors are buying into the strategy being pushed by the company in a pre-Easter roadshow that a push into more generic medicines will reap big rewards. That doesn’t chime with today’s spike though. Summat’s going on…
raptor66
16 Apr 2018
Re: Increase in price From Telegraph:Amid the recent flurry of deals in the healthcare sector, a surge in embattled pharma firm Vectura’s trading volume reignited long-standing bid rumours in the City as it soared 10.6p, or 11pc, to 104.5p.As Vectura’s trading volume hit eight times its average, City analysts speculated that Vectura losing some of its disgruntled shareholders since its strategy shift may have also relieved some of the selling pressure on the struggler. Pharma giants Novartis and GlaxoSmithKline have been among the names linked with Vectura, which slumped to its lowest level since 2012 in March.
raptor66
16 Apr 2018
Re: Increase in price Very high volumes today not seen for a long time.
dave297
16 Apr 2018
JPMorgan Their analysts consider we are still worth 180p per share so lets hope that they are right & that the massive increase in volume & recovery in our SP is based purely on the fact that they think we are oversold.It will be interesting to see where our new trading range settles & I hope it is higher than 100p as I wouldnt want any low ball bidders to be tempted to try & buy us cheaply & do an old fashioned asset strip ( ie the sum of the parts being worth more than the whole)
Matal
16 Apr 2018
On the up! April 12, 2018Reaffirmed: Vectura Group PLC (LON:VEC) Overweight Rating Reiterated by Analysts at JP Morgan Cazenove; GBX 180.00 Target in Place.Vectura Group PLC (LON:VEC) Rating Reaffirmed.Vectura Group PLC (LON:VEC) had their share rating of a ‘Overweight’ issued by research analysts at JP Morgan Cazenove, who now has a GBX 180.00 target price on the 599.57 million GBP market cap company or a 85.95 % upside potential.
raptor66
16 Apr 2018
Re: Increase in price Considerable 7m volume by 1030am could be due to some bid rumors again, at the back of other M&A news on Shire and Advent today.
